Intravesical Bacillus Calmette-Guerin for treating bladder cancer.
Bladder cancer continues to be a leading cause of malignant neoplasm in men. Since 1976, Bacillus Calmette-Guerin (BCG) has been a recommended treatment for superficial bladder malignancy. BCG treatment indications, administration, side effects, patient education, and nursing implications are discussed.
Boyd
Lee Ann
LA
Southwest Florida Urologic Associates, Cape Coral, FL, USA.
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000008:administration & dosage*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000601:surgery; D000075202:Contraindications; D006801:Humans; D008297:Male; D008875:Middle Aged; D024802:Nurse's Role; D010353:Patient Education as Topic; D018579:Patient Selection; D012307:Risk Factors; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000601:surgery
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine